OncoMatch

OncoMatch/Clinical Trials/NCT06535893

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

Is NCT06535893 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TN and TN-1 for breast cancer.

Phase 2RecruitingNagoya City UniversityNCT06535893Data as of May 2026

Treatment: TN · TN-1Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Disease stage

Required: Stage II, III

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify